<p>Hsa_circ_RNA_0011780 Represses the Proliferation and Metastasis of Non-Small Cell Lung Cancer by Decreasing FBXW7 via Targeting miR-544a</p>

Abstract

Circular RNA (circRNA) is involved in the development of various cancers. However, whether circRNA can inhibit the tumorigenesis of non-small cell lung cancer (NSCLC) is still unclear. We aimed to explore the epigenetic function of tumor-suppressive circRNA (hsa_circ_RNA_0011780) and its downstream regulatory factors in NSCLC. Patients and Methods: Quantitative polymerase chain reaction (qPCR) was used to evaluate hsa_circ_11780 expression in NSCLC tissues and cell lines. The impact of high hsa_circ_11780 expression on overall survival in patients with NSCLC was tested using the Log rank test. The association between decreased hsa_circ_11780 expression and clinicopathological features in patients with NSCLC was analyzed using the Chi-squared test. In vitro cell proliferation and apoptosis were assayed using the cell counting kit-8 (CCK-8) and flow cytometry, respectively. Mice xenograft models were used to determine the tumor promoting effects of hsa_circ_11780 on NSCLC in vivo. The underlying regulatory mechanism was predicted by bioinformatics and verified by a dual-luciferase reporter assay, RNA transfection, qPCR, and Western blotting. The correlation between miR-544a and hsa_-circ_11780 expression was verified using Spearman correlation coefficient. Results: The expression of hsa_circ_11780 in NSCLC tissues and cell lines strongly declined. Low hsa_circ_11780 expression is more likely to present in patients with a large tumor size (>3cm), distant metastasis, and poor overall survival. hsa_circ_11780 overexpression strongly inhibited proliferation, migration, and invasion of NSCLC cells (H226 and A549) in vitro and inhibited tumor growth in vivo. Furthermore, hsa_circ_11780 repressed miR-544a function by competitively binding to the complementary sites of miR-544a. miR-544a released by the declining expression of hsa_circ_11780 reduced the protein concentration of F-Box and WD repeat domain containing 7 (FBXW7) in NSCLC cells. Conclusion: FBXW7 expression mediated by the hsa_circ_11780/miR-544a axis is markedly associated with the proliferation, migration, and invasion of NSCLC, resulting in decreased survival. These findings suggest that this regulatory axis may serve as a novel therapeutic target in NSCLC.

Circular RNA CHST15 Sponges miR-155-5p and miR-194-5p to Promote the Immune Escape of Lung Cancer Cells Mediated by PD-L1

“…CircRNAs were abnormally expressed in different cancers (9,11). In lung cancer, studies found that the expressions of hsa_circ_0072083, CircZNF124, and CircABCB10 are up-regulated (12,14,15) but that of hsa_circ_11780, CircPTK2, and hsa_circ_0078767 are down-regulated (13,17,18). This study discovered the up-regulation of CircCHST15 in lung cancer tissues and cells, which was similar to the findings of Liu et al (16).…”

“…In recent decades, evidence has increasingly proven that circRNAs play crucial parts in cancer development, including lung cancer (9)(10)(11). For example, CircZNF124 can promote the progression of nonsmall cell lung cancer cells by targeting mIR-337-3p (12); hsa_circ_0011780 inhibits the proliferation and metastasis of lung cancer (13); down-regulated CircABCB10 enhances the sensitivity of lung cancer cells to cisplatin (14); hsa_circ_0072083 could promote the effect of cisplatin on suppressing the growth of lung cancer (15). Furthermore, a recent study discovered that CircCHST15 (hsa_circ_0109320) is differentially expressed in gefitinib-treated lung cancer and might be a biomarker for the treatment of lung cancer in the future (16).…”

<p>Circ_0000376, a Novel circRNA, Promotes the Progression of Non-Small Cell Lung Cancer Through Regulating the miR-1182/NOVA2 Network</p>

“…For instance, hsa_circ_0011780 has been proved to be an anti-cancer circRNA of NSCLC, which can inhibit the proliferation and metastasis of NSCLC cells. 13 CircCCDC66 is confirmed to play a pro-cancer role in NSCLC to accelerate cell growth and metastasis. 14 Therefore, circRNA is the key target to explore new biomarkers for cancer treatment.…”

Hsa_circ_0001073 targets miR‐626/LIFR axis to inhibit lung cancer progression

“…By performing the gain‐of‐function experiments, we found that circ_0001073 overexpression repressed lung cancer progression by reducing cell viability and invasion and enhancing apoptosis. This indicated that circ_0001073 played a suppressive role in lung cancer progression, which was like other circRNAs, such as circ_0011780, circ_0072309 and circ_0043265 27‐29 …”

“…This indicated that circ_0001073 played a suppressive role in lung cancer progression, which was like other circRNAs, such as circ_0011780, circ_0072309 and circ_0043265. [27][28][29] miRNAs play important roles in treatment of lung cancer by regulating 3' UTR of target mRNAs. 30 miR-626 usually functioned as an oncogenic miRNA in cancers.…”